BioSpace News Archive

Sientra, Inc., a medical aesthetics company exclusively focused on plastic surgery, announced its financial results for the second quarter ended June 30, 2021.

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced second quarter 2021 results and provided a corporate update.

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today reported its financial results for the second quarter ended June 30, 2021.

Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the EXALT™ Model B Single-Use Bronchoscope, designed for use in bedside procedures within the intensive care unit (ICU) and operating room (OR).

Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, is providing a company update and second quarter 2021 financial results.

The College of American Pathologists (CAP) new evidence-based clinical practice guideline, “Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies,” establishes recommendations that pathologists and clinicians can implement to better manage testing and improve the accurate diagnoses of patients with monoclonal gammopathies (MGs).

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced financial results for the three and six months ended June 30, 2021.

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the second quarter 2021, and provided an update on its clinical programs.

Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced its financial and operating results for the second quarter ended June 30, 2021 and provided a corporate update.